title: Antiestrogen Resistance and the Application of Systems Biology.
abstract: Understanding the molecular changes that drive an acquired antiestrogen resistance phenotype is of major clinical relevance. Previous methodologies for addressing this question have taken a single gene/pathway approach and the resulting gains have been limited in terms of their clinical impact. Recent systems biology approaches allow for the integration of data from high throughput "-omics" technologies. We highlight recent advances in the field of antiestrogen resistance with a focus on transcriptomics, proteomics and methylomics.
authors.affiliation: Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, U.S.A.
authors.forename: Kerrie B
authors.initials: KB
authors.lastname: Bouker
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.forename: Jianhua
authors.initials: J
authors.lastname: Xuan
authors.forename: Robert
authors.initials: R
authors.lastname: Clarke
keywords: Systems biology; antiestrogens; breast cancer; estrogens
references.citation: Nat Rev Cancer. 2011 Jun 16;11(7):523-32
references.pmid: 21677677
references.citation: Cancer Lett. 2009 Aug 8;280(2):184-91
references.pmid: 19185986
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4111-9
references.pmid: 20697068
references.citation: PLoS One. 2012;7(7):e40466
references.pmid: 22808167
references.citation: Cell. 2005 Jul 15;122(1):33-43
references.pmid: 16009131
references.citation: Cancer Res. 1995 Aug 1;55(15):3331-8
references.pmid: 7614468
references.citation: Cancer Lett. 2011 Dec 26;313(1):26-43
references.pmid: 21955614
references.citation: FASEB J. 2007 Dec;21(14):4013-27
references.pmid: 17660348
references.citation: J Natl Cancer Inst. 2011 Apr 20;103(8):662-73
references.pmid: 21421860
references.citation: Mol Cell Proteomics. 2009 Jun;8(6):1278-94
references.pmid: 19329653
references.citation: J Proteome Res. 2011 Oct 7;10(10):4567-78
references.pmid: 21936522
references.citation: Cancer Res. 2004 Jun 1;64(11):4030-9
references.pmid: 15173018
references.citation: Cancer Res. 2006 Jun 15;66(12):6370-8
references.pmid: 16778215
references.citation: Br J Cancer. 2011 Jun 7;104(12):1828-35
references.pmid: 21559012
references.citation: BMC Syst Biol. 2011 May 09;5:67
references.pmid: 21554733
references.citation: Nat Rev Cancer. 2009 Sep;9(9):631-43
references.pmid: 19701242
references.citation: BMC Syst Biol. 2011 Oct 12;5:161
references.pmid: 21992556
references.citation: Endocr Relat Cancer. 2001 Sep;8(3):175-82
references.pmid: 11566608
references.citation: Mol Syst Biol. 2010 Dec 21;6:456
references.pmid: 21179027
references.citation: Endocrinology. 2003 Oct;144(10):4562-74
references.pmid: 12959972
references.citation: Mol Cancer Ther. 2005 Jan;4(1):33-41
references.pmid: 15657351
references.citation: Genome Biol. 2004;5(9):R66
references.pmid: 15345050
references.citation: J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):8-20
references.pmid: 19444933
references.citation: BMC Bioinformatics. 2011 Mar 22;12:82
references.pmid: 21426557
references.citation: Horm Mol Biol Clin Investig. 2011 Mar;5(1):35-44
references.pmid: 23930139
references.citation: J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):71-84
references.pmid: 11384865
references.citation: BMC Genomics. 2008 May 22;9:239
references.pmid: 18498629
references.citation: Cancer Res. 2006 Dec 15;66(24):11954-66
references.pmid: 17178894
references.citation: J Clin Oncol. 2005 Feb 1;23(4):732-40
references.pmid: 15681518
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5036-42
references.pmid: 18711169
references.citation: Nat Genet. 2011 Jan;43(1):27-33
references.pmid: 21151129
references.citation: Nat Rev Cancer. 2008 Jan;8(1):37-49
references.pmid: 18097463
references.citation: Nature. 2012 Sep 6;489(7414):91-100
references.pmid: 22955619
references.citation: BMC Genomics. 2011 Dec 05;12:593
references.pmid: 22142239
references.citation: J Cell Biochem. 2006 Aug 1;98(5):1163-84
references.pmid: 16514628
references.citation: PLoS One. 2010 Jan 06;5(1):e8604
references.pmid: 20062536
references.citation: Br J Cancer. 2008 Mar 25;98(6):1023-8
references.pmid: 18283324
references.citation: Expert Rev Anticancer Ther. 2011 Aug;11(8):1283-94
references.pmid: 21916582
references.citation: Trends Endocrinol Metab. 1996 Oct;7(8):291-301
references.pmid: 18406762
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15732-7
references.pmid: 19706389
references.citation: Eur J Cancer. 2007 Jul;43(11):1679-86
references.pmid: 17601725
references.citation: Cancer Res. 2011 Oct 1;71(19):6195-207
references.pmid: 21825015
references.citation: PLoS Comput Biol. 2011 Oct;7(10):e1002240
references.pmid: 22028643
references.citation: Cancer Res. 2003 Nov 1;63(21):7158-66
references.pmid: 14612509
references.citation: Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1109-15
references.pmid: 9865429
references.citation: BMC Syst Biol. 2010 Dec 17;4:170
references.pmid: 21167036
references.citation: Bioinformatics. 2012 Aug 1;28(15):1990-7
references.pmid: 22595208
references.citation: Breast Cancer (Auckl). 2012;6:47-66
references.pmid: 22399860
references.citation: Cancer Res. 2005 May 15;65(10):4101-17
references.pmid: 15899800
references.citation: Am J Pathol. 2010 May;176(5):2113-30
references.pmid: 20348243
references.citation: Cancer Res. 2002 Jun 15;62(12):3428-37
references.pmid: 12067985
references.citation: J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):83-92
references.pmid: 22265958
references.citation: Cancer Inform. 2011;10:185-204
references.pmid: 21869864